News Story: Full Text
Sponsored By
NovoCure Trial
Please Click On The Above Banner For More Details
Braintumor Website

 

Celldex vaccine improves long-term brain cancer survival in study

Al's Comment:

 Amazing results.  25% of patients with recurrent gbm alive after 2 years compared with NONE in the control group!  The FDA should try to get this approved as soon as possible. We shouldn't have to wait years for another study.


IF the story does not appear below, Click HERE to view the text of the story!
Note: The original website is displayed below - we have no control over it and are not responsible for the content of it, we just report it! IF you click on anything below, it will take you off of our website!
Original Source: http://www.reuters.com/article/2015/11/20/us-celldex-glioblastoma-idUSKCN0T92OS20151120#PC7DDDj8iG87sZyq.97


(Everything below this line is from VirtualTrials.com!)

Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740